Back to Agenda
Symposium – Frailty as a Baseline Stratification Parameter and Potential Therapeutic Target
Session Chair(s)
Florian von Raison, DrMed
Senior Global Program Head and Chairman Geriatric Medicine Working Party/ EFGCP
Novartis Pharma AG, Switzerland
Progress made in drug development for and with older people? This session will announce and discuss the brand new EMA Geriatric Working Party frailty definition selected for study baseline characteristics for clinical studies and propose how this will change the research landscape in geriatric studies in Europe and beyond.
Speaker(s)
The EMA Geriatric Medicines Strategy, Good Pharmacovigilance Practice (GVP) and What Leads Us to Single out Frailty
Susan Morgan
MHRA, United Kingdom
Medical Assessor
SPRINTT- IMI
Susanna Del Signore
Bluecompanion Ltd, United Kingdom
Director and Founder
The Frailty Guideline under Consultation: What Does It Mean in Terms of CT Population and Registries?
Antonio Cherubini, MD
IRCCS-INRCA, Italy
Professor
Addressing Areas of Need / Insufficient Research
Cynthia A Bens
Personalized Medicine Coalition, United States
Senior Vice President, Public Policy
Roundtable discussion
Francesca Cerreta, PharmD, MPharm, MS
European Medicines Agency, Netherlands
Principal Scientific Officer
Have an account?